JP2016506722A5 - - Google Patents

Download PDF

Info

Publication number
JP2016506722A5
JP2016506722A5 JP2015554120A JP2015554120A JP2016506722A5 JP 2016506722 A5 JP2016506722 A5 JP 2016506722A5 JP 2015554120 A JP2015554120 A JP 2015554120A JP 2015554120 A JP2015554120 A JP 2015554120A JP 2016506722 A5 JP2016506722 A5 JP 2016506722A5
Authority
JP
Japan
Prior art keywords
invasive
deltac
strong
cancer
infectious
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015554120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506722A (ja
JP6382223B2 (ja
Filing date
Publication date
Priority claimed from EP13305086.4A external-priority patent/EP2759301A1/en
Application filed filed Critical
Publication of JP2016506722A publication Critical patent/JP2016506722A/ja
Publication of JP2016506722A5 publication Critical patent/JP2016506722A5/ja
Application granted granted Critical
Publication of JP6382223B2 publication Critical patent/JP6382223B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015554120A 2013-01-24 2014-01-20 癌治療における、遺伝的に改変された、増強されたアポトーシス促進性を有する感染性麻疹ウイルス(mv−deltacウイルス)の使用 Active JP6382223B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305086.4A EP2759301A1 (en) 2013-01-24 2013-01-24 Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
EP13305086.4 2013-01-24
PCT/EP2014/051063 WO2014114605A1 (en) 2013-01-24 2014-01-20 Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (mv-deltac virus) in cancer therapy

Publications (3)

Publication Number Publication Date
JP2016506722A JP2016506722A (ja) 2016-03-07
JP2016506722A5 true JP2016506722A5 (cg-RX-API-DMAC7.html) 2016-10-20
JP6382223B2 JP6382223B2 (ja) 2018-08-29

Family

ID=47683672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015554120A Active JP6382223B2 (ja) 2013-01-24 2014-01-20 癌治療における、遺伝的に改変された、増強されたアポトーシス促進性を有する感染性麻疹ウイルス(mv−deltacウイルス)の使用

Country Status (11)

Country Link
US (3) US9889193B2 (cg-RX-API-DMAC7.html)
EP (2) EP2759301A1 (cg-RX-API-DMAC7.html)
JP (1) JP6382223B2 (cg-RX-API-DMAC7.html)
CN (1) CN107223055A (cg-RX-API-DMAC7.html)
BR (1) BR112015017692B1 (cg-RX-API-DMAC7.html)
CA (1) CA2898370C (cg-RX-API-DMAC7.html)
DK (1) DK2948157T3 (cg-RX-API-DMAC7.html)
ES (1) ES2700749T3 (cg-RX-API-DMAC7.html)
PL (1) PL2948157T3 (cg-RX-API-DMAC7.html)
RU (1) RU2700083C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014114605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2759301A1 (en) * 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
CN107085095A (zh) * 2017-03-02 2017-08-22 江苏华冠生物技术股份有限公司 用作酶联试剂盒包被抗原的麻疹病毒裂解液的制备方法
US11633441B2 (en) 2017-12-01 2023-04-25 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain
CN117323421A (zh) * 2022-06-24 2024-01-02 中国医学科学院医学生物学研究所 一种流感病毒介导的抗肿瘤疫苗及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
EP2058003A1 (en) * 2007-10-10 2009-05-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Medicaments and methods for treating mesothelioma
EP2420242A1 (en) * 2010-08-20 2012-02-22 Lauer, Ulrich M. Oncolytic measles virus
US9399062B2 (en) * 2011-01-18 2016-07-26 Christopher D. Richardson PVRL4 (Nectin4) is a receptor for measles virus
EP2759301A1 (en) * 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)

Similar Documents

Publication Publication Date Title
Yang et al. Tumor cell membrane‐based vaccines: A potential boost for cancer immunotherapy
Fang et al. Emerging nano-/biotechnology drives oncolytic virus-activated and combined cancer immunotherapy
Kuang et al. The design of peptide-amphiphiles as functional ligands for liposomal anticancer drug and gene delivery
Alemany Viruses in cancer treatment
CN111344398A (zh) 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
JP2016531927A5 (cg-RX-API-DMAC7.html)
WO2016192451A1 (zh) 一种溶瘤病毒制剂及其制备方法
Bahreyni et al. A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy
Garmaroudi et al. Therapeutic efficacy of oncolytic viruses in fighting cancer: recent advances and perspective
Escobar et al. Engineered tumor-infiltrating macrophages as gene delivery vehicles for interferon-α activates immunity and inhibits breast cancer progression
Hani et al. Current perspectives on novel drug delivery systems and approaches for management of cervical cancer: a comprehensive review
Liu et al. Therapeutic use of tumor cell-derived extracellular vesicles
Bin Liu et al. Virus, oncolytic virus and human prostate cancer
Kingsak et al. Therapeutic potential of oncolytic viruses in the era of precision oncology
JP2016533373A5 (cg-RX-API-DMAC7.html)
Kooti Esmaeili Gouvarchin Ghaleh H, Farzanehpour M, Dorostkar R, Jalali Kondori B and Bolandian M (2021) Oncolytic Viruses and Cancer, Do You Know the Main Mechanism? Front
Ghosh et al. Exploring the potential of oncolytic viral vectors in targeted cancer therapy: advances, challenges and future directions
RU2015128913A (ru) Применение генетически модифицированного патогенного вируса кори с улучшенными проапоптотическими свойствами (вирус mv-deltac) в терапии рака
JP2019532635A5 (cg-RX-API-DMAC7.html)
Hernandez-Alcoceba et al. Gene therapy of liver cancer
JP5964818B2 (ja) 乳がんのウイルス療法用薬剤
CN108495934B (zh) 将腺病毒和化学治疗剂组合用于治疗癌症
Vorobyev et al. Oncolytic viruses in the therapy of lymphoproliferative diseases
Schirrmacher Molecular mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic newcastle disease virus. Biomedicines. 2022; 10 (3): 562
Zargaran et al. Boosting immune response against cervical cancer: A combined approach using oncolytic virus and targeted therapies